Bicara Therapeutics Inc. (BCAX) Q2 FY26 Earnings Call

Fortify HNO1 remains on track for year-end enrollment and a mid-2027 interim analysis, but spending will increase.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-08-11
Length43 minutes
EPS$-0.82
EPS consensus$-0.77
Revenue$4.6M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q4 FY25

Read the full Q2 FY26 earnings call transcript

All BCAX earnings · Back to BCAX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.